M&T Bank Corp Supernus Pharmaceuticals, Inc. Transaction History

M&T Bank Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 09, 2018	SELL	$42.7 - $56.55 $322,128 - $426,613	-7,544 Closed	0 $0
Q2 2018 Aug 10, 2018	SELL	$44.1 - $59.85 $70,956 - $96,298	-1,609 Reduced 17.58%	7,544 $452,000
Q1 2018 May 04, 2018	SELL	$37.15 - $46.9 $52,567 - $66,363	-1,415 Reduced 13.39%	9,153 $419,000
Q4 2017 Feb 06, 2018	BUY	$36.4 - $42.6 $143,088 - $167,460	3,931 Added 59.23%	10,568 $422,000
Q3 2017 Nov 13, 2017	BUY	$36.75 - $49.65 $61,850 - $83,560	1,683 Added 33.97%	6,637 $266,000
Q2 2017 Aug 11, 2017	BUY	N/A	4,954	4,954 $213,000

283

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.11B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

Stay updated on M&T Bank Corp with notifications on news.